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ABSTRACT
Severe nosocomial infections and multidrug resistance (MDR) are associated with a poor prognosis for
patients in intensive care units. This is partly because most of these patients suffer from high disease
severity and acute illness before the onset of infection. Nevertheless, the mortality attributed directly to
infection can also be devastating. However, the attributable mortality can be limited by taking account of
a number of key points. General infection prevention measures, prevention of cross-transmission and a
policy of restricted antimicrobial use are all important because of their positive influence on the rates of
infection and MDR. In turn, this will increase the odds for successful empirical coverage of the causative
microorganism. Once infection occurs, benefits are to be expected from early recognition of the septic
episode and prompt initiation of empirical antimicrobial therapy. The choice of empirical therapy
should be based on the local bacterial ecology and patterns of resistance, the presence of risk-factors for
MDR, and the colonisation status of the patient. Attention should also be given to adequate doses of
antimicrobial agents and, if possible, elimination of the sources of infection, e.g., contaminated devices
or intra-abdominal collections or leakages. In the latter case, timely surgical intervention is essential. In
addition, haemodynamic stabilisation and optimisation of tissue oxygenation can save lives.
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INTRODUCTION
Despite increasing efforts toward prevention,
nosocomial infection remains one of the most
important complications associated with hospi-
talisation, with patients admitted to intensive care
units (ICUs) being at particular risk for nosoco-
mial infection. A European point-prevalence
study revealed that c. 45% of ICU patients have
an infection, and that this infection was acquired
within the ICU in 21% of cases [1]. The highest
infection rates were observed among patients
with multiple trauma and burn injuries, among
medical patients, and among patients who had
undergone urgent abdominal surgery, whereas
lower infection rates were observed among
patients who underwent elective surgery, espe-
cially neurosurgery.
The high incidence of nosocomial infection
among ICU patients is caused by a number of
factors. During recent decades, the number of
invasive techniques used for diagnosis and ther-
apy has increased significantly, implying easier
access for microorganisms to otherwise sterile
body sites. In addition, there have been changes
in the patient population admitted to ICUs. The
number of patients receiving immunosuppressive
therapy has grown, which increases the risk of
infection, in particular by opportunistic patho-
gens such as Candida spp. [2,3]. Besides these risk-
factors, advances in supportive treatment and
emergency medicine have led to improved sur-
vival rates, creating a group of long-term ICU
residents with a high risk of infection. The most
frequent nosocomial infections are respiratory
tract infections, which usually occur in patients
receiving mechanical ventilation, followed by
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high rates of bloodstream infections, urinary tract
infections and wound infections [1].
The problem of nosocomial infection in the ICU
is enhanced by the emergence of microorganisms
with multidrug resistance (MDR). For example,
data from the National Nosocomial Infections
Surveillance system in the USA revealed that, in
1989–1998, the relative risk (RR) of isolating
methicillin-resistant Staphylococcus aureus from
ICU patients was 1.09 (95% CI 1.07–1.16) as
compared with non-ICU patients [4]. The RR for
enterococci being resistant to vancomycin was
1.16 (95% CI 1.13–1.20), and the risk of a Klebsiella
pneumoniae isolate being resistant to third-gener-
ation cephalosporins was 24% higher among ICU
patients (RR 1.24; 95% CI 1.20–1.30). Data from
1999, i.e., only 1 year later, clearly demonstrated
an apparent ongoing emergence of MDR in ICUs
in the USA [5]. Factors in ICUs that promote
antimicrobial MDR include cross-transmission
through failure of infection prevention measures,
impaired host defence caused by the debilitated
condition of many critically-ill patients, and
excessive use of antimicrobial agents [4].
Nosocomial infection and MDR both poten-
tially compromise an ICU patient’s chance of
survival [6–8]. However, the deleterious effects of
infection and resistance can be limited substan-
tially. In this respect, much attention has been
given to increasing the use of appropriate empir-
ical therapy [9,10]. Yet, optimising the odds of
survival for critically-ill infected patients involves
more than selecting the proper drug. This review
highlights several ways to limit the attributable
mortality of severe nosocomial infections and the
associated antimicrobial resistance.
ASSOCIATED VS. ATTRIBUTABLE
MORTALITY
Severity of underlying disease and acute illness
are the most important risk-factors for the acqui-
sition of severe nosocomial infection. As a conse-
quence, the mortality associated with this
complication is very high. In many cases, the
prognosis for patients affected by severe nosoco-
mial infections is already very poor before the
onset of the infection. In other words, even in the
absence of a severe infection, a substantial num-
ber of these patients would not survive hospital-
isation. It is therefore necessary to distinguish
mortality caused by the severity of the underlying
disease from mortality caused by the infection.
In addition to differences in disease severity,
patients who develop nosocomial infection often
have a longer period of hospitalisation. This
additional period of hospitalisation is mostly
accounted for by the period before the onset of
the infection, thereby, again, stressing the
difference in patient profile between cases with
and without nosocomial infection.
Disease severity and exposure time are consid-
ered to be the most important factors that poten-
tially confound estimates of the impact of
nosocomial infection [11]. In order to make a
reliable estimate of the effect of infection, adjust-
ment for differences in these characteristics is
necessary [12]. Matched-cohort studies are
designed specifically to deal with this issue. In a
matched-cohort study, outcome is compared
between a group of subjects with nosocomial
infection and a group without, with both groups
having a similar distribution of patient character-
istics influencing the risk of infection and out-
come [13]. As potential confounders are present
and distributed equally in both groups, it is
assumed that the effect of confounding will be
minimised. The quality of a matched-cohort
analysis will depend on the quality of the match-
ing procedure, allowing for comparison between
cases and controls that have similar outcome
expectancies a priori. In matched-cohort studies,
the crude mortality of the control group is
considered to be the mortality caused by the
general severity of underlying disease and acute
illness. The mortality among infected cases in
excess of the mortality in the control group is
considered to be the mortality caused by the
nosocomial infection. Hence, the attributable
mortality is calculated by subtracting the crude
mortality of the controls from the mortality of the
cases [14].
Attributable mortality: the modifiable
proportion
Numerous matched-cohort studies have been
performed during the past decade with the
objective of estimating the attributable mortality
of nosocomial infection in ICUs. However, as
revealed by the many conflicting studies in the
literature, focusing on the attributable mortality
instead of the associated mortality does not
provide greater clarity. Most matched-cohort
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studies have involved patients with nosocomial
bloodstream infection. While some studies have
reported dramatic attributable mortality rates of
20–35% [15–19], others have failed to demonstrate
any significant increase in mortality [20–27]. In
general, attributable mortality rates appear to be
higher for cases of secondary bloodstream infec-
tion, while most studies of primary and ⁄ or
catheter-related bloodstream infection have not
revealed significant attributable mortality [28–31].
Similarly, studies of patients with ventilator-
associated pneumonia have also revealed con-
flicting results. In a review of the clinical impact
of this particular infection, Safdar et al. [32] found
that estimates of attributable mortality varied
from 0 to 50%. In addition to the type of infection,
the attributable mortality may differ according to
the causative pathogen and its antimicrobial
susceptibility pattern [12,33]. Antimicrobial resis-
tance hampers a favourable outcome by decreas-
ing the chance of appropriate empirical
antimicrobial therapy. The relationship between
antimicrobial resistance and ⁄ or inappropriate
empirical antimicrobial therapy, and decreased
odds of survival, has already been demonstrated
[7,22,34,35]. Consequently, modifying the resis-
tance factor should be one of the principal aims in
order to limit the burden of nosocomial infection.
While the huge differences in attributable
mortality may be confusing, they also highlight
the fact that it is truly possible to reduce the
burden of nosocomial infection. However, it
should be clearly understood that efforts to limit
the clinical impact of severe infection can only
affect the fraction of mortality that is actually a
consequence of the infection.
STEPS TO LIMIT THE ATTRIBUTABLE
MORTALITY
Enhanced infection prevention
Hand hygiene and other basic universal precau-
tions remain cornerstones in the prevention of
infection. It is obvious that well-thought-out
multifaceted programmes to promote measures
for infection prevention may change behaviour as
well as attitudes towards strategies, resulting in
reduced nosocomial infection rates [36]. Although
less evident at first sight, infection prevention also
has a favourable impact on attributable mortality
(Fig. 1). Adequate infection prevention leads to
reduced rates of infection and, consequently, to
reduced consumption of antimicrobial agents
which, in turn, slows down the emergence of
MDR. Lower MDR rates are associated with
higher rates of appropriate antimicrobial therapy,
which, as already mentioned, affect patient out-
come favourably. In addition, strict application of
preventive measures will cause a shift in the ICU
population experiencing nosocomial infection.
While a general decrease in the infection rate will
take place, a relative increase will be noted among
the most critically-ill subjects. As the level of
Enhanced infection
prevention and control
↓Antimicrobial consumption
↓Cross-transmission
↓ Infections
↓ Involvement of 
MDR microorganisms
Infections limited
to high-risk patients
↓Emergence of MDR
↓ Inappropriate
antimicrobial therapy
↓Attributable
mortality
Fig. 1. Relationship between enhan-
ced efforts in infection prevention
and reduced attributable mortality
rates. MDR, multidrug resistance.
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infection prevention increases, the only targets
left for nosocomial pathogens will be the most
vulnerable patients. As already outlined above,
patients with a high risk of infection generally
have a poor prognosis. For this reason, the impact
of an additional complication (e.g., nosocomial
infection) is less significant. Kim et al. [37] dem-
onstrated that the adjusted risk of mortality for
patients with a lower initial severity of illness
who developed a bloodstream infection was more
than twice as high as that for patients without
infection and with a similar initial severity of
illness (hazard ratio 2.42; 95% CI 1.70–3.44) [37].
In contrast, patients with a higher initial severity
of illness who developed a bloodstream infection
did not have an increased risk of death (hazard
ratio 0.96; 95% CI 0.76–1.23). Thus, in brief, if
nosocomial infection is successfully limited to the
most vulnerable and critically-ill patients in the
unit, the mortality attributable to infection in this
particular cohort of patients will be small.
Avoidance of cross-transmission
Prevention of cross-transmission of epidemiolog-
ically important nosocomial pathogens, e.g.,
methicillin-resistant Staphylococcus aureus or
Gram-negative bacteria producing extended-
spectrum b-lactamases, will have a similar
beneficial effect. Reduced spread of multidrug-
resistant pathogens will allow physicians to
prescribe fewer last-resort antimicrobial agents,
and a reduced involvement of MDR in nosoco-
mial infections will have a favourable effect on the
frequency of appropriate therapy (Fig. 1).
Reduction of MDR through limiting
antimicrobial consumption
Besides failure of infection control, use of antimi-
crobial agents is one of the main factors contrib-
uting to the emergence of MDR. A key element in
this respect is to limit antimicrobial prophylaxis to
evidence-based indications such as standard pre-
operative prophylaxis. In order to reduce the
emergence of MDR, antibiotic dosing should be
adequate, taking into account the increased extra-
cellular fluid content in septic patients, and
courses of antibiotics should not be longer than
needed [38–40]. In a randomised trial involving
patients with ventilator-associated pneumonia,
Chastre et al. [41] demonstrated that antibiotic
treatment for 8 days was as effective as a 15-day
course, and was also associated with less devel-
opment of MDR in cases of recurrent infection
(42% vs. 62% of pulmonary recurrences, p 0.04).
Although such data are not available for intra-
abdominal infections, it is likely that, under the
conditions of adequate surgical source control, a
1-week antibiotic course will be adequate for most
cases [42].
In order to support a more rational use of
antimicrobial agents, establishment of an antimi-
crobial consumption control programme can have
a beneficial effect in terms of optimising prescrib-
ing habits and reducing MDR [43,44]. Specific
characteristics and quality indicators for such
antibiotic control programmes have been
described previously [45] and are outside the
scope of this review.
Early recognition of signs of sepsis
Adequate anti-infective management starts with
early recognition of clinical signs of sepsis and ⁄ or
infection. In this context, an important role exists
for the nursing staff. Nurses must be aware of
clinical signs raising suspicion of systemic infec-
tion [46,47]. A protocol of standing orders indi-
cating when and how to take blood cultures (or
cultures from other relevant body sites) must be
available. It should also be clear when to alert the
attending physician in order to avoid delay in
taking further steps.
Prompt initiation of empirical antimicrobial
therapy
Once cultures have been taken, the start of
antimicrobial therapy should not be postponed
until the microbiological results are available. The
relationship between early appropriate therapy
and enhanced survival has been demonstrated on
several occasions [9]. Failure to combat the caus-
ative pathogen adequately within the critical
time-frame of the first 24–48 h clearly adds to
the risk of mortality [21,34,48]. However, in an era
of MDR, achieving a high rate of appropriate
empirical therapy presents a significant challenge
for ICU physicians. Two strategies have been
described that have the aim of optimising the
frequency of appropriate empirical therapy.
First, the Tarragona strategy [49] involves
evaluating the risk of involvement of multidrug-
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resistant pathogens, e.g., methicillin-resistant
Staphylococcus aureus or Acinetobacter baumannii.
Such an evaluation takes into account the length
of hospitalisation, previous antibiotic exposure,
and current local bacterial ecology. If risk-factors
for MDR involvement are present, broad-spec-
trum antimicrobial agents are recommended (i.e.,
carbapenems or glycopeptides). However, be-
cause of the frequent use of last-resort antimicro-
bial agents when following this approach, a
thorough diagnostic investigation is recom-
mended in order to de-escalate the initial antimi-
crobial therapy whenever possible. Nevertheless,
in routine practice, the causative pathogen cannot
be identified in up to 30% of patients with
pneumonia; consequently, de-escalation is only
possible for a minority of such patients, and
(possibly unnecessary) prolonged use of last-
resort antimicrobial agents occurs in the remain-
ing patients [50]. However, such an approach
clearly works in terms of achieving a high rate of
appropriate empirical therapy, as demonstrated
by Rello et al. [51] and Leone et al. [52], who
observed the use of inappropriate therapy in only
9% and 13%, respectively, of patients with
ventilator-associated pneumonia.
Second, an approach for initiating empirical
therapy based on regular surveillance cultures
has been proposed as a valuable alternative to the
Tarragona strategy. Such a surveillance-assisted
approach seeks to achieve a balance between
optimising the likelihood of appropriate therapy
and respecting the local bacterial ecology by
saving last-resort antimicrobial agents for patients
who are colonised with pathogens requiring such
therapy. In this strategy, everything depends on
the use of surveillance cultures to predict the
causative pathogen. Most published information
has concerned nosocomial pneumonia. Michel
et al. [53] found that endotracheal surveillance
cultures predicted the aetiology of bronchoalveolar-
confirmed ventilator-associated pneumonia in
83% of cases, leading to a 95% frequency of
appropriate therapy. Depuydt et al. [54] found
that tracheal surveillance cultures predicted an
MDR aetiology of bacteraemic pneumonia in 70%
of cases, while limiting antibiotic consumption in
comparison with what would have been pre-
scribed if national guidelines for nosocomial
pneumonia had been followed, and thereby
reducing the microbial selection pressure on the
local microbial population. The same study also
demonstrated an improved outcome as a conse-
quence of higher rates of appropriate therapy for
patients with bacteraemic pneumonia when the
aetiology was predicted by the surveillance cul-
tures [55]. The performance of this strategy is
strongly dependent on the frequency at which
surveillance cultures are taken. Studies sampling
tracheal surveillance cultures once-weekly failed
to demonstrate an advantage of this strategy
[56,57], but other studies demonstrated benefits of
a surveillance-assisted approach when the sam-
pling frequency was at least twice-weekly [53–
55,58].
Regular surveillance cultures also have value in
the case of non-respiratory infections. In a subset
of patients with bacteraemia caused by multi-
drug-resistant Gram-negative bacteria, Blot et al.
[59] showed that 75% of the episodes were
preceded by overt colonisation (manifest in either
aspirate, urine, oral or rectal samples) with
an identical microorganism with an identical
antibiogram to that causing the bacteraemia [59].
Identification of colonisation preceding bacter-
aemia was associated with a significantly higher
rate of appropriate empirical therapy (RR 1.9,
95% CI 1.1–3.1). This study demonstrated that
the percentage of bacteraemia preceded by colo-
nisation increased according to the length of stay
in the ICU; among cases of bacteraemia that
developed during the first week of ICU stay, 44%
were preceded by colonisation, but this percent-
age increased to 91% for episodes that occurred
after 28 days in the ICU.
Rapid reporting of culture results
Another important factor in achieving a high
index of appropriate antimicrobial therapy is
rapid reporting of the microbiological results
(species identification and sensitivity testing). In
this way, an empirical regimen that is not
appropriate for the causative pathogen can be
corrected within the clinically important time-
frame of 48 h. In such cases, rapid microbial
testing and reporting might add significantly to
the quality of anti-infective management by
minimising the deleterious effect of delayed
appropriate therapy [60–62]. Whenever possible,
downgrading to a drug with a narrower spec-
trum of activity should occur in order to avoid
unnecessary antibiotic pressure, with consequent
risks of developing MDR. Frequent and routine
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contacts among clinical microbiologists, infec-
tious disease consultants and physicians are
useful to optimise local antimicrobial policies.
Such multidisciplinary expert systems have
succeeded in attaining better clinical and eco-
nomic outcomes [46,63,64].
Adequate dosing of antimicrobial agents
Pathophysiological conditions may sometimes
contribute to antimicrobial drug under-exposure
in critically-ill patients, especially those experi-
encing septic shock. Variations in distribution
volume and ⁄ or renal impairment are the most
relevant and frequent pathophysiological mecha-
nisms that may affect drug disposition in ICU
patients [65]. In contrast to healthy volunteers and
non-critically-ill patients, some of these situations
may promote significant changes in drug avail-
ability by altering distribution and ⁄ or elimination
processes. Consequently, these factors should be
taken into account when prescribing antimicro-
bial agents for severe infections.
Unfortunately, little is known concerning the
influence of variations in distribution volumes in
critically-ill septic patients on drug availability at
the site of infection [66]. As a rule, hydrophilic
antibiotics (e.g., b-lactams, aminoglycosides and
glycopeptides) and renally excreted, lipophilic
antibiotics (e.g., ciprofloxacin, gatifloxacin and
levofloxacin) require subsequent and repeated
dosage adjustments [39,65].
Elimination of the source of infection
Whenever the source of infection can be eradi-
cated, this should be done as soon as possible.
Invasive devices are one of the most frequent
causes of nosocomial bloodstream infection, and
their use should consequently be limited when-
ever possible [67,68]. In cases with clinical signs of
sepsis without apparent focus, all central venous
catheters should be removed without delay. It can
be assumed that the possibility of removing the
source of the bloodstream infection is responsible
for the observation that catheter-related blood-
stream infections have a better outcome than
bloodstream infections involving secondary
sources [28,30].
In the context of intra-abdominal infections,
surgical intervention to control the source is
essential to treat the infection [42,69]. However,
the presence of infection must first be evident, as
surgical exploration in the absence of infection
might adversely affect the prognosis for critically-
ill patients [70]. The concept of source control
includes three principles that contribute to more
efficacious microbial eradication and clinical
recovery: drainage, debridement, and restoration
of anatomy and function [71].
Adequate organ support
For patients with severe sepsis or septic shock,
efforts to achieve haemodynamic stabilisation and
tissue oxygenation must be initiated immediately.
Aggressive fluid administration and vasopressors
might be needed to achieve the following goals: a
central venous pressure of 8–12 mmHg, a mean
arterial pressure >65 mmHg, a urine output
>0.5 mL ⁄ kg ⁄h, and a central venous oxygen
saturation of 70%. Realising these goals within
6 h of the onset of sepsis has been shown in a
randomised controlled trial to decrease in-hospi-
tal mortality from 46.5% to 30.5% [72]. Additional
organ support, either respiratory, renal, metabolic
or haematological, is highly desirable to achieve a
favourable outcome [73].
CONCLUSIONS
Severe nosocomial infection, as well as MDR, is
associated with a poor prognosis in ICU patients.
However, the attributable mortality can be limited
by taking into account a number of key points.
General infection prevention measures, preven-
tion of cross-transmission and a policy of
restricted antimicrobial use are all important
because of their positive influence on infection
rates and the involvement of multidrug-resistant
pathogens, which increases the odds of empirical
coverage of the causative microorganism. Once
infection occurs, benefits are to be expected from
early recognition of the septic episode and
prompt initiation of empirical antimicrobial ther-
apy. The choice of empirical therapy depends on
the local bacterial ecology, the presence of risk-
factors for MDR involvement, and the colonisa-
tion status of the patient. Attention should also be
given to adequate dosing of antimicrobial agents
and the elimination of potential sources of infec-
tion, e.g., contaminated devices, intra-abdominal
collections or leakages. In the last of these cases,
timely surgical intervention is a first priority. In
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addition, haemodynamic stabilisation and opti-
misation of tissue oxygenation can save lives.
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